Arrowhead Pharmaceuticals, Inc. (ARWR) - Stock Analysis
Last updated: Jun 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Arrowhead Pharmaceuticals (ARWR) is a near-term hot idea driven by FDA approval of REDEMPLO®, strong cash runway through 2028, positive clinical pipeline progress, ongoing trials with milestone potential, and robust bullish technical momentum (+12% price rise over three weeks) amidst solid industry sentiment.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong Liquidity • Revenue Decline • Loss Rebound ARWR has strong liquidity and net cash, but recent revenue collapsed and losses widened, leaving the stock expensive relative to current fundamentals.
Price Behavior
Key Price Behavior Insights: • Range-bound trade • Support defended • Resistance capped Support Level: $70.82-$71.00 Resistance Level: $78.70-$79.70 ARWR remains rangebound and slightly weaker, with $71 support holding but repeated failures near $79 keeping the short-term setup fragile.
Sentiment & News
Key News Insights: • Commercial launch • Pipeline progress • Upcoming catalysts Arrowhead Pharmaceuticals is transitioning into a more commercial phase after REDEMPLO approval while continuing to deliver encouraging RNAi pipeline data and upcoming clinical catalysts across cardiometabolic programs.
AI Summary
ARWR should now be viewed less as a pure platform story and more as an early commercial biotech with real funding capacity—nearly $1.8B in cash and positive quarterly cash flow—but the investment case now hinges on execution, because REDEMPLO uptake, payer access, and the upcoming plozasiran readout must accelerate meaningfully to justify its still-rich valuation and avoid a re-rate lower.
Description
Arrowhead Pharmaceuticals is a Pasadena-based biopharmaceutical company, founded in 1989, that develops RNA interference therapeutics for a range of liver, cardiovascular, pulmonary, rare genetic and oncology indications. Its clinical-stage pipeline includes candidates targeting liver-expressed proteins, cardiovascular lipid regulators, pulmonary targets and other disease-specific genes, and the company partners with Janssen and Takeda on several liver-directed programs. Arrowhead also participates in collaborations for subcutaneously administered RNAi candidates for chronic hepatitis B and other externally developed programs.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 4 | Feb 11 | ARWR | Arrowhead Pharmaceuticals, Inc. | Arrowhead Pharmaceuticals (ARWR) is a near-term hot idea driven by FDA approval of REDEMPLO®, strong cash runway through 2028, positive clinical pipeline progress, ongoing trials with milestone potential, and robust bullish technical momentum (+12% price rise over three weeks) amidst solid industry sentiment. | Closed | -9.6% |
| Dec 2 | Dec 9 | ARWR | Arrowhead Pharmaceuticals, Inc. | Near-term growth opportunity following FDA approval of REDEMPLO (first siRNA therapy for familial chylomicronemia syndrome), Breakthrough Therapy designation for another indication, $200M Novartis upfront payment, and 32.7% price surge supported by strong technical breakout. | Closed | +18.8% |